Dr. Sunil S. Desai

Intensive Care Medicine | Pulmonary Medicine | Sleep Medicine
1000 Remington Blvd, Suite 100, 
Bolingbrook, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
1000 Remington Blvd, Suite 100, 
Bolingbrook, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sunil Desai is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Bolingbrook, Illinois. Dr. Desai is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Pulmonary Medicine
Sleep Medicine
Licenses
Critical Care Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1000 Remington Blvd, Suite 100, Bolingbrook, IL 60440
Other Locations
1222 S Orange Ave, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Other
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: Oral Repotrectinib (TPX-0005)
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: ITMHA, Dexamethasone, Mitoxantrone, Pegaspargase, Asparaginase Erwinia Chrysanthemi, Bortezomib, Vorinostat, Cyclophosphamide, Mercaptopurine, Methotrexate, Leucovorin Calcium, Cytarabine, Etoposide, Vincristine
Study Phase: Phase 1/Phase 2
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2025
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Other
Key Adverse Events After Childhood Cancer
Key Adverse Events After Childhood Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Other
A COG Study for Collecting and Banking Ewing Sarcoma Specimens
A COG Study for Collecting and Banking Ewing Sarcoma Specimens
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Dinutuximab, Irinotecan Hydrochloride, Sargramostim, Temozolomide, Temsirolimus
Study Phase: Phase 2
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Enrollment Status: Completed
Publish Date: July 19, 2018
Intervention Type: Other
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
Enrollment Status: Completed
Publish Date: July 16, 2018
Intervention Type: Other
View 14 Less Clinical Trials

2 Total Publications

Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study.
Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 05, 2017
Similar Doctors
Expertise in
15
conditions
Dr. Daniel F. Dilling
Intensive Care Medicine | Pulmonary Medicine
Expertise in
15
conditions
Dr. Daniel F. Dilling
Intensive Care Medicine | Pulmonary Medicine

Loyola University Medical Center

1 S260 Summit Ave, 
Oakbrook Terrace, IL 
 (13.9 miles away)
630-953-6600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Daniel Dilling is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Oakbrook Terrace, Illinois. Dr. Dilling is highly rated in 15 conditions, according to our data. His top areas of expertise are Lymphangioleiomyomatosis, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Lung Transplant, and Gastrostomy. Dr. Dilling is currently accepting new patients.

Expertise in
6
conditions
Dr. Babak B. Mokhlesi
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Expertise in
6
conditions
Dr. Babak B. Mokhlesi
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

Rush University Medical Group

1725 W Harrison St, Suite 10, 
Chicago, IL 
 (26.2 miles away)
312-942-6744
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Babak Mokhlesi is a Pulmonary Medicine specialist and a Sleep Medicine provider in Chicago, Illinois. Dr. Mokhlesi is highly rated in 6 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Excessive Daytime Sleepiness, Central Sleep Apnea, and Adenoidectomy. Dr. Mokhlesi is currently accepting new patients.

Expertise in
26
conditions
Dr. Raju Z. Abraham
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Expertise in
26
conditions
Dr. Raju Z. Abraham
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

Riverside Health System

135 W Station St, 
Saint Anne, IL 
 (49.6 miles away)
815-427-8189
Experience:
43+ years
Languages Spoken:
English, Malayalam
See accepted insurances

Raju Abraham is a Pulmonary Medicine specialist and a Sleep Medicine provider in Saint Anne, Illinois. Dr. Abraham has been practicing medicine for over 43 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Lung Nodules, Lung Metastases, Pneumonia, Gastrostomy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Desai's expertise for a condition
ConditionClose

We do not have enough information to identify the Areas of Expertise for this provider.

Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile